Keyphrases
Acute Myeloid Leukemia
15%
Advanced Breast Cancer
11%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
51%
Anti-CD19 chimeric Antigen Receptor T Cells
8%
BRCA Carriers
7%
BRCA mutation
10%
BRCA mutation Carriers
10%
BRCA1, BRCA2
14%
Breast
8%
Breast Cancer
39%
Breast Cancer Patients
14%
Breast Cancer Subtypes
8%
Breast Cancer Treatment
7%
Cancer Characteristics
7%
Chemotherapy
26%
Chimeric Antigen Receptor T-cell Therapy
8%
Confidence Interval
20%
Disease-free Survival
11%
Early Breast Cancer
26%
Estrogen Receptor-positive
9%
Fludarabine
14%
Graft-versus-host Disease (GvHD)
18%
Granulocyte Colony-stimulating Factor (G-CSF)
8%
Hazard Ratio
17%
High Risk
10%
Hormone Receptor-positive
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
12%
Human Epidermal Growth Factor Receptor 2-negative
7%
Meta-analysis
9%
Metastatic Breast Cancer
9%
Multivariate Analysis
8%
Myelodysplastic Syndrome
7%
Non-relapse Mortality
16%
Odds Ratio
7%
Oncotype DX
11%
Ovarian Cancer
7%
Overall Survival
26%
Patients with Breast Cancer
8%
Phase II Trial
13%
Progression-free Survival
11%
Recurrence Score
9%
Reduced-intensity Conditioning
11%
Relapsed or Refractory
10%
Stem Cell Transplantation
10%
Transplantation
8%
Trastuzumab
12%
Treosulfan
7%
Triple-negative Breast Cancer
8%
Tumor
8%
Unrelated Donor
10%
Medicine and Dentistry
Acute Graft Versus Host Disease
6%
Acute Myelogenous Leukemia
6%
Acute Myeloid Leukemia
17%
Adverse Event
7%
Allogeneic Hematopoietic Stem Cell Transplantation
18%
Allogeneic Stem Cell Transplantation
20%
BRCA Mutation
8%
BRCA1
16%
Breast Cancer
100%
Cancer
8%
Cell Transplantation
6%
Chimeric Antigen Receptor T-Cell
9%
Chimeric Antigen Receptor T-Cell Immunotherapy
8%
Cisplatin
6%
Clinical Trial
6%
Cohort Analysis
6%
Conditioning
7%
Cumulative Incidence
7%
Disease
34%
Disease Free Survival
10%
Epidermal Growth Factor Receptor 2
16%
Estrogen Receptor
12%
Fludarabine
12%
Gamma Urogastrone
16%
Graft Versus Host Reaction
11%
Hazard Ratio
14%
Hematopoietic Stem Cell
6%
Hormone Receptor
9%
Large-Cell Lymphoma
8%
Malignant Neoplasm
8%
Meta-Analysis
7%
Metastatic Breast Cancer
8%
Multivariate Analysis
7%
Myelodysplastic Syndrome
6%
Neoplasm
22%
Non-Hodgkin Lymphoma
8%
Odds Ratio
7%
Ovarian Cancer
7%
Overall Survival
28%
Prognostic Factor
6%
Progression Free Survival
11%
Prospective Study
6%
Recurrence Risk
6%
Recurrent Disease
12%
Reduced Intensity Conditioning
11%
Salvage Therapy
7%
Stem Cell Therapy
11%
Talazoparib
7%
Trastuzumab
8%
Triple Negative Breast Cancer
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
9%
Adverse Event
6%
Breast Cancer
73%
Capecitabine
6%
Chemotherapy
38%
Chimeric Antigen Receptor
7%
Cisplatin
6%
Cohort Study
6%
Disease
18%
Disease Free Survival
8%
Epidermal Growth Factor Receptor 2
12%
Estrogen Receptor
11%
Fludarabine
8%
Gamma Urogastrone
12%
Graft Versus Host Reaction
5%
Granulocyte Colony Stimulating Factor
7%
Metastatic Breast Cancer
12%
Myelodysplastic Syndrome
5%
Neoplasm
15%
Nonhodgkin Lymphoma
5%
Ovary Cancer
5%
Overall Survival
23%
Paclitaxel
5%
Progression Free Survival
10%
Recurrent Disease
9%
Remission
7%
Talazoparib
5%
Trastuzumab
12%
Trastuzumab Deruxtecan
5%
Treosulfan
6%
Triple Negative Breast Cancer
7%